When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AKRO - Akero Therapeutics: A Very Attractive Risk/Reward Opportunity
Akero Therapeutics Inc.
In our previous assessment, we compared 13 NASH drug candidates, and our favorite was AK-001 of Akero Therapeutics (AKRO). We emphasized the high likelihood of Akero Therapeutics to reach the best results in NASH treatment among the 2nd wave NASH drug candidates. For those who are interested, please click here.
Released data confirmed our previous assessment. Now, we would like to draw a more detailed conclusion about Akero Therapeutics, its drug candidate, and possible future prospects. We would like to share our opinion why we are still holding our long positions and why the